TG Therapeutics (TGTX) is back in focus after management reaffirmed its 2026 revenue guidance for BRIUMVI, highlighted rapid physician uptake in multiple sclerosis, and noted a busy schedule of pipeline readouts in the coming years.

Despite strong 2025 results and the recent azer cel milestone, TG Therapeutics’ 7 day share price return of 6.05% and 90 day share price return of 5.62% point to fading near term momentum, while the 3 year total shareholder return of 73.52% contrasts with a 1 year total shareholder return decline of 17.51%.

If TG Therapeutics has you thinking more broadly about MS and autoimmune treatments, it could be worth scanning 32 healthcare AI stocks as another way to spot potential opportunities in this space.

So with TG Therapeutics trading around US$29.03 after a 1 year total shareholder return decline of 17.51% but a 3 year total shareholder return of 73.52%, is the recent weakness a reset that offers upside, or is the market already factoring in potential future growth?

Most Popular Narrative: 35% Undervalued

With TG Therapeutics last closing at $29.03 versus a narrative fair value of $44.43, the current market price sits well below that central estimate, and the gap hinges on how investors see BRIUMVI’s long term potential and the broader pipeline.

The planned launch of subcutaneous (subcu) BRIUMVI is a significant upcoming catalyst, as it could unlock access to 35-40% of the anti-CD20 MS market segment currently dominated by self-administered therapies, greatly increasing BRIUMVI's addressable market and supporting long-term revenue growth.

Curious what kind of revenue ramp, margin profile and future earnings multiple are baked into that $44.43 fair value and discount rate assumptions? The full narrative walks through how faster top line growth, rising profitability and a rerating in the earnings multiple are combined to justify a value well above today’s price.

Result: Fair Value of $44.43 (UNDERVALUED)

However, the story can change quickly if BRIUMVI underperforms expectations, or if rival MS therapies and pricing pressure start to squeeze volumes and margins.

Next Steps

With sentiment on TG Therapeutics clearly mixed, this is the moment to look through the full picture yourself and act on your own judgment, starting with 4 key rewards and 1 important warning sign.

Ready to hunt for more investment ideas?

If TG Therapeutics has sharpened your thinking, do not stop here. Use the Simply Wall St screener to line up your next set of clear, data backed ideas.

• Target potential mispricings by scanning 47 high quality undervalued stocks that pair quality fundamentals with prices that do not fully reflect their underlying strength.
• Prioritise resilience by reviewing 73 resilient stocks with low risk scores where business stability and lower risk scores are front and center.
• Get ahead of the crowd by checking our screener containing 24 high quality undiscovered gems that combine solid fundamentals with limited current market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.